Short Interest in Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Grows By 797.8%

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) was the recipient of a significant growth in short interest in the month of August. As of August 31st, there was short interest totaling 34,223 shares, a growth of 797.8% from the August 15th total of 3,812 shares. Based on an average daily trading volume, of 114,861 shares, the days-to-cover ratio is currently 0.3 days. Currently, 0.0% of the company’s shares are short sold.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on SGIOY. The Goldman Sachs Group upgraded shares of Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a report on Monday, June 15th. Jefferies Financial Group raised Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a report on Tuesday, July 14th. Finally, Zacks Research upgraded Shionogi & Co., Ltd. Unsponsored ADR from a “strong sell” rating to a “hold” rating in a research report on Monday, May 25th. Two investment analysts have rated the stock with a Strong Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy”.

Shionogi & Co., Ltd. Unsponsored ADR Stock Up 0.2%

SGIOY stock traded up $0.02 during mid-day trading on Thursday, reaching $9.04. The company had a trading volume of 202,000 shares, compared to its average volume of 81,849. Shionogi & Co., Ltd. Unsponsored ADR has a 52 week low of $7.65 and a 52 week high of $12.00. The company has a market capitalization of $15.39 billion, a price-to-earnings ratio of 9.04, a PEG ratio of 3.23 and a beta of 0.08. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.14 and a quick ratio of 1.46. The stock has a 50 day simple moving average of $8.96 and a two-hundred day simple moving average of $9.60.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) last announced its quarterly earnings results on Monday, August 3rd. The company reported $0.36 earnings per share for the quarter, beating the consensus estimate of $0.18 by $0.18. The company had revenue of $1.04 billion during the quarter, compared to analysts’ expectations of $970.69 million. Shionogi & Co., Ltd. Unsponsored ADR had a return on equity of 16.13% and a net margin of 46.67%. As a group, equities analysts predict that Shionogi & Co., Ltd. Unsponsored ADR will post 0.82 earnings per share for the current fiscal year.

About Shionogi & Co., Ltd. Unsponsored ADR

Shionogi & Co, Ltd. is a Japan-based pharmaceutical company that researches, develops, manufactures and markets prescription medicines. Founded in Osaka in 1878, the company has built its business around drug discovery and has a particular focus on infectious diseases, including antiviral and antibacterial treatments.

Shionogi’s products include Xofluza (baloxavir marboxil), an oral treatment for influenza, and Fetcroja (cefiderocol), an antibiotic used for certain difficult-to-treat bacterial infections.